GIP and type 2 diabetes mellitus: Tirzepatide, marketed under the brand name Mounjaro, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that was authorized for use in type 2 diabetes in May 2022 [1].